Morgan Stanley
FHTX icon

Morgan Stanley’s Foghorn Therapeutics FHTX Stock Holding History

Morgan Stanley’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Sell
92,096
-6,380
-6% -$28.3K ﹤0.01% 5596
2026
Q1 		$471K Sell
98,476
-23,251
-19% -$128K ﹤0.01% 5515
2025
Q4 		$657K Buy
121,727
+58,051
+91% +$263K ﹤0.01% 5378
2025
Q3 		$311K Sell
63,676
-15,877
-20% -$84.2K ﹤0.01% 5713
2025
Q2 		$374K Buy
79,553
+10,082
+15% +$42.1K ﹤0.01% 5596
2025
Q1 		$254K Sell
69,471
-28,074
-29% -$128K ﹤0.01% 5636
2024
Q4 		$460K Sell
97,545
-10,656
-10% -$77.6K ﹤0.01% 5447
2024
Q3 		$1.01M Buy
108,201
+43,103
+66% +$312K ﹤0.01% 5035
2024
Q2 		$374K Sell
65,098
-9,872
-13% -$58.8K ﹤0.01% 5424
2024
Q1 		$503K Sell
74,970
-30,143
-29% -$167K ﹤0.01% 5305
2023
Q4 		$678K Buy
105,113
+32,866
+45% +$142K ﹤0.01% 5160
2023
Q3 		$361K Sell
72,247
-16,121
-18% -$124K ﹤0.01% 5311
2023
Q2 		$622K Sell
88,368
-5,199
-6% -$36.4K ﹤0.01% 5108
2023
Q1 		$580K Sell
93,567
-207,999
-69% -$1.36M ﹤0.01% 5167
2022
Q4 		$1.92M Sell
301,566
-734,549
-71% -$5.54M ﹤0.01% 4497
2022
Q3 		$8.89M Sell
1,036,115
-185,347
-15% -$2.39M ﹤0.01% 3105
2022
Q2 		$16.6M Buy
1,221,462
+192,736
+19% +$2.49M ﹤0.01% 2490
2022
Q1 		$15.7M Buy
1,028,726
+476,821
+86% +$6.54M ﹤0.01% 2381
2021
Q4 		$12.6M Sell
551,905
-427,322
-44% -$6.14M ﹤0.01% 2675
2021
Q3 		$13.6M Sell
979,227
-982
-0.1% -$10.9K ﹤0.01% 2543
2021
Q2 		$10.5M Buy
980,209
+586,487
+149% +$6.39M ﹤0.01% 2922
2021
Q1 		$5.19M Buy
393,722
+350,978
+821% +$5.75M ﹤0.01% 3367
2020
Q4 		$867K Buy
+42,744
New +$819K ﹤0.01% 4749

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Morgan Stanley's FHTX Position: Q2 2026 in Review

Morgan Stanley reduced its Foghorn Therapeutics (FHTX) stake by 6.5% in Q2 2026, selling an estimated $28.3K and leaving 92,096 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #5596.

Morgan Stanley first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $16.6M in Q2 2022. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Morgan Stanley held 92,096 shares of Foghorn Therapeutics worth $449K as of Q2 2026.
  • Morgan Stanley sold 6,380 Foghorn Therapeutics shares in Q2 2026, an estimated $28.3K.
  • Foghorn Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5596 holding.
  • Morgan Stanley first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Foghorn Therapeutics position peaked at $16.6M in Q2 2022.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.